glp 1 and cognitive function Potential Role of Glucagon-like Peptide-1 Receptor Agonists in the Treatment of Decline Dementia in Diabetes Mellitus GLP-1 and the Degenerating Brain:
Description
p = 0.0113), RR: 0.81 (95% CI: 0.68, 0.95
Finally, the 3/6/9/12 mg group received 3 mg for the first two weeks, 6 mg for weeks 34, 9 mg for weeks 58, and 12 mg for weeks 912
Brunner said overdosing also occurs with the brand-name versions of the drugs and is not limited to compounded medications
Subcutaneous injections were used to administer all therapy doses once a day
Now is the time to get started
The work is mainly aimed at boosting efficacy, making patient convenience a bit easier, and pushing therapeutic use beyond diabetes management, like more metabolic needs
